Amended Statement of Ownership (sc 13g/a)

Date : 02/15/2017 @ 7:13AM
Source : Edgar (US Regulatory)
Stock : Zynerba Pharmaceuticals, Inc. (MM) (ZYNE)
Quote : 17.04  -0.22 (-1.27%) @ 8:00PM

Amended Statement of Ownership (sc 13g/a)

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. ___2____)*

 

Zynerba Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

98986X109

(CUSIP Number)

 

December 31, 2016

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨   Rule 13d-1(b)
þ   Rule 13d-1(c)
¨   Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

     
CUSIP No. 98986X109 13G Page 2 of 5 Pages

 

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

G-TEN Partners LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)     ¨
(b)     þ
3. SEC USE ONLY
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware, United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5. SOLE VOTING POWER
 
0
  6. SHARED VOTING POWER
 
556,571*
  7. SOLE DISPOSITIVE POWER
 
0
  8. SHARED DISPOSITIVE POWER
 
556,571*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

556,571*
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)     ¨
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.6%*
12. TYPE OF REPORTING PERSON (see instructions)

PN

 

 

 

 

     
CUSIP No. 98986X109 13G Page 3 of 5 Pages

 

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Ethan Benovitz
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)     ¨
(b)     ¨
3.

SEC USE ONLY 

 

4. CITIZENSHIP OR PLACE OF ORGANIZATION
 

United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5. SOLE VOTING POWER
 
0
  6. SHARED VOTING POWER
 
742,928*
  7. SOLE DISPOSITIVE POWER
 
0
  8. SHARED DISPOSITIVE POWER
 
742,928*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

742,928*
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)     ¨
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.5%*
12. TYPE OF REPORTING PERSON (see instructions)

IN, HC

 

 

 

 

     
CUSIP No. 98986X109 13G Page 4 of 5 Pages

 

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Jaime Hartman
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)     ¨
(b)     ¨
3.

SEC USE ONLY

 

4. CITIZENSHIP OR PLACE OF ORGANIZATION
 

United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5. SOLE VOTING POWER
 
0
  6. SHARED VOTING POWER
 
742,928*
  7. SOLE DISPOSITIVE POWER
 
0
  8. SHARED DISPOSITIVE POWER
 
742,928*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

742,928*
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)     ¨
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.5%*
12. TYPE OF REPORTING PERSON (see instructions)

IN, HC

 

 

 

 

     
CUSIP No. 98986X109 13G Page 5 of 5 Pages

 

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Genesis Capital Advisors LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)     ¨
(b)     þ
3. SEC USE ONLY
   
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware, United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5. SOLE VOTING POWER
 
186,357*
  6. SHARED VOTING POWER
 
556,571*
  7. SOLE DISPOSITIVE POWER
 
186,357*
  8. SHARED DISPOSITIVE POWER
 
556,571*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

742,928*
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)     ¨
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.5%*
12. TYPE OF REPORTING PERSON (see instructions)

OO

 

 

 

 

Item 1.

 

  (a) Name of Issuer
Zynerba Pharmaceuticals, Inc.
     
  (b)

Address of Issuer’s Principal Executive Offices
80 W. Lancaster Avenue, Suite 300

Devon, PA 19333

 

Item 2.

 

  (a)

Name of Person Filing
G-TEN Partners LLC

Ethan Benovitz

Jaime Hartman

Genesis Capital Advisors LLC

     
  (b)

Address of the Principal Office or, if none, residence
1212 Avenue of the Americas, 19 th Floor

New York, NY 10036

     
  (c)

Citizenship
G-TEN Partners LLC – Delaware, United States

Ethan Benovitz – United States

Jaime Hartman – United States

Genesis Capital Advisors LLC – Delaware, United States

     
  (d) Title of Class of Securities
Common Stock, par value $0.001 per share
     
  (e) CUSIP Number
98986X109

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

 

 

 

  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4.  Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned:

 

G-TEN Partners LLC – 556,571*

Genesis Capital Advisors LLC – 742,928*

Jaime Hartman - 742,928*

Ethan Benovitz - 742,928*

     
  (b)

Percent of class:

 

G-TEN Partners LLC – 5.6%*

Genesis Capital Advisors LLC – 7.5%*

Jaime Hartman – 7.5%*

Ethan Benovitz – 7.5%*

     
  (c) Number of shares as to which the person has:
       
    (i)

Sole power to vote or to direct the vote

 

G-TEN Partners LLC – 0*

Genesis Capital Advisors LLC – 186,357*

Jaime Hartman - 0*

Ethan Benovitz - 0*

       
    (ii)

Shared power to vote or to direct the vote

 

G-TEN Partners LLC – 556,571*

Genesis Capital Advisors LLC – 556,571*

Jaime Hartman – 742,928*

Ethan Benovitz – 742,928*

       
    (iii)

Sole power to dispose or to direct the disposition of

 

G-TEN Partners LLC – 0*

Genesis Capital Advisors LLC – 186,357*

Jaime Hartman - 0*

Ethan Benovitz - 0*

       
    (iv)

Shared power to dispose or to direct the disposition of

 

G-TEN Partners LLC – 556,571*

Genesis Capital Advisors LLC – 556,571*

Jaime Hartman – 742,928*

Ethan Benovitz – 742,928*

 

 

 

 

Instruction . For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

 

*The shares of common stock (the "Shares") of Zynerba Pharmaceuticals, Inc. (the "Company") reported herein are held by Genesis Capital Advisors LLC (the “Adviser”), as well as G-TEN Partners LLC (the “Fund”), which is managed by the Adviser. Ethan Benovitz (“Benovitz”) and Jaime Hartman (“Hartman”), as individuals, act as co-investment managers to the Fund and as managing members of GCA. The Adviser, in its capacity as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all Shares held by the Fund. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser, Hartman and Benovitz may be deemed to beneficially own an aggregate of 742,928 Shares, or 7.5% of Shares deemed issued and outstanding as of November 11, 2016. The beneficial ownership percentages reported herein are based on 9,953,718 voting Shares issued and outstanding as of November 11, 2016, as disclosed in the Company's Quarterly Report filed with the Securities and Exchange Commission on November 14, 2016. This report shall not be deemed an admission that the Adviser, the Funds and Accounts or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨ .

 

Instruction . Dissolution of a group requires a response to this item.

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Item 8.  Identification and Classification of Members of the Group.

 

Item 9.  Notice of Dissolution of Group.

 

Item 10.  Certification.

 

  (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
       
  (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

 

 

 

 

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2017 G-TEN Partners LLC
  By: Genesis Capital Advisors LLC
  Its Investment Manager
     
  By: /s/ Ethan Benovitz
  Name: Ethan Benovitz
  Title: Managing Member
   
  Genesis Capital Advisors LLC
     
  By: /s/ Ethan Benovitz
  Name: Ethan Benovitz
  Title: Managing Member
   
  Ethan Benovitz
     
  By: /s/ Ethan Benovitz
  Individually
   
  Jaime Hartman
     
  By: /s/ Jaime Hartman
  Individually

 

 

 

 

JOINT FILING STATEMENT

PURSUANT TO RULE 13D-1(K)(1)

 

The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 2 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.001 per share, of Zynerba Pharmaceuticals, Inc., together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule13G.

 

This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

 

Dated: February 14, 2017 G-TEN Partners LLC
  By: Genesis Capital Advisors LLC
  Its Investment Manager
     
  By: /s/ Ethan Benovitz
  Name: Ethan Benovitz
  Title: Managing Member
   
  Genesis Capital Advisors LLC
     
  By: /s/ Ethan Benovitz
  Name: Ethan Benovitz
  Title: Managing Member
   
  Ethan Benovitz
     
  By: /s/ Ethan Benovitz
  Individually
   
  Jaime Hartman
     
  By: /s/ Jaime Hartman
  Individually

 

 

 

ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Historical Stock Chart

1 Year : From Jul 2016 to Jul 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Intraday Stock Chart

Today : Wednesday 26 July 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

Latest ZYNE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.